Atara Biotherape Financials
Atara Biotherape (ATRA) reported $120.8M in revenue for fiscal year 2025, down 6.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025’s reported profitability came from a sharp cost reset, while cash outflow and liquidity strain still dominated.
Revenue slipped6.3% in FY2025, but R&D spending fell75.3% ; that explains why the income statement turned positive without showing that the business became self-funding. The proof is cash conversion: despite net income of$32.7M , operations still burned$50.9M , so profitability and liquidity moved in opposite directions.
This business remains R&D-led rather than asset-heavy: capital spending was
The balance-sheet posture tightened further, with cash at
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Atara Biotherape's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Atara Biotherape scores -127.29, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($92.3M) relative to total liabilities ($58.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Atara Biotherape passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Atara Biotherape used $1.56 of operating cash (-$50.9M OCF vs $32.7M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Atara Biotherape earns $9.46 in operating income for every $1 of interest expense ($35.9M vs $3.8M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Atara Biotherape generated $120.8M in revenue in fiscal year 2025. This represents a decrease of 6.3% from the prior year.
Atara Biotherape's EBITDA was $38.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 148.4% from the prior year.
Atara Biotherape reported $32.7M in net income in fiscal year 2025. This represents an increase of 138.3% from the prior year.
Cash & Balance Sheet
Atara Biotherape recorded an outflow of $50.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 26.1% from the prior year.
Atara Biotherape held $8.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Atara Biotherape's operating margin was 29.7% in fiscal year 2025, reflecting core business profitability. This is up 94.4 percentage points from the prior year.
Atara Biotherape's net profit margin was 27.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 93.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Atara Biotherape invested $37.4M in research and development in fiscal year 2025. This represents a decrease of 75.3% from the prior year.
Atara Biotherape reported no capital expenditure in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Not reported for fiscal year 2025.
ATRA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $630K+22.1% | $516K-67.6% | $1.6M-53.8% | $3.5M-80.4% | $17.6M-82.1% | $98.1M+199.7% | $32.8M-18.5% | $40.2M |
| R&D Expenses | $1.3M+720.1% | $164K-26.5% | -$223K-92.4% | $2.9M-60.0% | $7.3M-73.4% | $27.4M-4.5% | $28.7M-34.6% | $43.9M |
| SG&A Expenses | $3.8M+6.0% | $3.6M-15.9% | $4.3M+7.3% | $4.0M-38.8% | $6.5M-43.2% | $11.5M+21.6% | $9.4M-9.4% | $10.4M |
| Operating Income | -$4.7M-40.1% | -$3.4M-31.4% | -$2.6M+28.3% | -$3.6M-211.8% | $3.2M-91.8% | $38.8M+418.0% | -$12.2M+43.9% | -$21.8M |
| Interest Expense | $191K-77.0% | $830K-7.2% | $894K-1.7% | $909K-6.5% | $972K-4.4% | $1.0M0.0% | $1.0M-14.0% | $1.2M |
| Income Tax | $1K | $0 | $0-100.0% | $28K+833.3% | $3K | $0+100.0% | -$19K-11.8% | -$17K |
| Net Income | -$4.8M-16.6% | -$4.1M-21.7% | -$3.4M+20.8% | -$4.3M-280.3% | $2.4M-93.7% | $38.0M+399.5% | -$12.7M+42.1% | -$21.9M |
| EPS (Diluted) | -$0.32-10.3% | -$0.29 | -$0.36-12.5% | -$0.32-268.4% | $0.19-94.6% | $3.50 | -$0.07 | -$2.93 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
ATRA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.0M+5.1% | $20.0M-1.2% | $20.2M-32.9% | $30.2M-18.3% | $36.9M-40.5% | $62.0M-43.1% | $109.1M-23.6% | $142.7M |
| Current Assets | $13.5M+11.1% | $12.2M-0.3% | $12.2M-33.7% | $18.4M-25.6% | $24.8M-8.9% | $27.2M-58.1% | $64.9M-29.4% | $91.9M |
| Cash & Equivalents | $3.2M-61.5% | $8.4M-1.4% | $8.5M+47.7% | $5.7M-66.0% | $16.9M+22.1% | $13.8M-44.7% | $25.0M-46.1% | $46.5M |
| Inventory | N/A | N/A | $0 | $0 | $0 | $0-100.0% | $10.7M-23.8% | $14.0M |
| Accounts Receivable | $318K | $0-100.0% | $1.3M-34.5% | $1.9M | $0-100.0% | $8.9M+498.9% | $1.5M+11.0% | $1.3M |
| Total Liabilities | $58.0M+1.2% | $57.3M-2.4% | $58.7M-12.1% | $66.8M-7.1% | $71.9M-38.6% | $117.1M-43.3% | $206.4M-11.5% | $233.2M |
| Current Liabilities | $6.8M+21.3% | $5.6M-62.2% | $14.9M-17.4% | $18.1M+24.0% | $14.6M-69.6% | $47.9M-64.4% | $134.6M-13.7% | $156.0M |
| Total Equity | -$37.0M+0.8% | -$37.3M+3.1% | -$38.5M-5.1% | -$36.6M-4.5% | -$35.0M+36.4% | -$55.1M+43.4% | -$97.3M-7.4% | -$90.5M |
| Retained Earnings | -$2.0B-0.2% | -$2.0B-0.2% | -$2.0B-0.2% | -$2.0B-0.2% | -$2.0B+0.1% | -$2.0B+1.9% | -$2.1B-0.6% | -$2.0B |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
ATRA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.3M-8.6% | -$3.1M+46.1% | -$5.7M+41.8% | -$9.8M-33.7% | -$7.3M+74.0% | -$28.1M-15.0% | -$24.5M-513.5% | -$4.0M |
| Capital Expenditures | N/A | N/A | $0 | $0 | $0 | $0-100.0% | $90K | $0 |
| Free Cash Flow | N/A | N/A | -$5.7M+41.8% | -$9.8M-33.7% | -$7.3M+74.0% | -$28.1M-14.6% | -$24.6M-515.7% | -$4.0M |
| Investing Cash Flow | -$6.6M | $0-100.0% | $8.4M+448.6% | -$2.4M+52.2% | -$5.1M-129.5% | $17.2M+409.4% | $3.4M+120.3% | -$16.7M |
| Financing Cash Flow | $4.8M+63.5% | $3.0M+98466.7% | -$3K-100.3% | $1.0M-93.2% | $15.3M+6221.6% | -$250K+23.8% | -$328K-100.9% | $35.8M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ATRA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -749.2% | -652.9% | -160.7% | -103.5% | 18.2%-21.3pp | 39.5%+76.8pp | -37.3%+16.9pp | -54.1% |
| Net Margin | -767.3% | -803.3% | -213.5% | -124.6% | 13.6%-25.1pp | 38.7%+77.5pp | -38.8%+15.8pp | -54.5% |
| Return on Assets | -23.0%-2.3pp | -20.7%-3.9pp | -16.8%-2.6pp | -14.3%-20.7pp | 6.5%-54.8pp | 61.3%+72.9pp | -11.6%+3.7pp | -15.3% |
| Current Ratio | 1.98-0.2x | 2.16+1.3x | 0.82-0.2x | 1.02-0.7x | 1.70+1.1x | 0.57+0.1x | 0.48-0.1x | 0.59 |
| FCF Margin | N/A | N/A | -357.2% | -283.4% | -41.6%-13.0pp | -28.7%+46.3pp | -75.0%-65.1pp | -9.9% |
Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$38.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.82), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Atara Biotherape Ranks
Frequently Asked Questions
What is Atara Biotherape's annual revenue?
Atara Biotherape (ATRA) reported $120.8M in total revenue for fiscal year 2025. This represents a -6.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Atara Biotherape's revenue growing?
Atara Biotherape (ATRA) revenue declined by 6.3% year-over-year, from $128.9M to $120.8M in fiscal year 2025.
Is Atara Biotherape profitable?
Yes, Atara Biotherape (ATRA) reported a net income of $32.7M in fiscal year 2025, with a net profit margin of 27.1%.
What is Atara Biotherape's EBITDA?
Atara Biotherape (ATRA) had EBITDA of $38.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Atara Biotherape's operating margin?
Atara Biotherape (ATRA) had an operating margin of 29.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Atara Biotherape's net profit margin?
Atara Biotherape (ATRA) had a net profit margin of 27.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Atara Biotherape's free cash flow?
Atara Biotherape (ATRA) recorded an outflow of $50.9M in free cash flow during fiscal year 2025. This represents a 26.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Atara Biotherape's operating cash flow?
Atara Biotherape (ATRA) recorded an outflow of $50.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Atara Biotherape's total assets?
Atara Biotherape (ATRA) had $20.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Atara Biotherape's capital expenditures?
Atara Biotherape (ATRA) reported no capital expenditure during fiscal year 2025.
How much does Atara Biotherape spend on research and development?
Atara Biotherape (ATRA) invested $37.4M in research and development during fiscal year 2025.
What is Atara Biotherape's current ratio?
Atara Biotherape (ATRA) had a current ratio of 0.82 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Atara Biotherape's return on assets (ROA)?
Atara Biotherape (ATRA) had a return on assets of 161.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Atara Biotherape's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Atara Biotherape (ATRA) held $8.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $50.9M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Atara Biotherape's debt-to-equity ratio negative or not reported?
Atara Biotherape (ATRA) has negative shareholder equity of -$38.5M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Atara Biotherape's Altman Z-Score?
Atara Biotherape (ATRA) has an Altman Z-Score of -127.29, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Atara Biotherape's Piotroski F-Score?
Atara Biotherape (ATRA) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Atara Biotherape's earnings high quality?
For every $1 of reported earnings, Atara Biotherape (ATRA) used $1.56 of operating cash (-$50.9M OCF vs $32.7M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Atara Biotherape cover its interest payments?
Atara Biotherape (ATRA) has an interest coverage ratio of 9.46x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Atara Biotherape?
Atara Biotherape (ATRA) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.